| Melissa Rendeiro Gregorio, CNM | |
|
136 Sherman Ave, New Haven, CT 06511-5238 | |
| (203) 562-5181 | |
| Not Available |
| Full Name | Melissa Rendeiro Gregorio |
|---|---|
| Gender | Female |
| Speciality | Advanced Practice Midwife |
| Location | 136 Sherman Ave, New Haven, Connecticut |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447595632 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | (* (Not Available)) | Primary |
| Entity Name | Yale University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205822236 PECOS PAC ID: 9436061736 Enrollment ID: O20031105000015 |
News Archive
BioParadox, Inc., a regenerative medicine company pioneering point-of-care biologic treatments for cardiovascular disease, today announced data supporting the use of VitaKine- Platelet Cell Therapy as a promising treatment for heart attack patients.
Researchers demonstrated that Lactobacillus rhamnosus can dose-dependently reestablish a balanced intestinal microbiome and counter the liver-damaging effects of alcohol consumption in mice to reverse the results of chronic alcohol-induced liver injury.
For the first time, MIT neuroscientists have shown they can control muscle movement by applying optogenetics - a technique that allows scientists to control neurons' electrical impulses with light - to the spinal cords of animals that are awake and alert.
Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that it has granted PROCAPS S.A. exclusive rights to market and sell DAVANAT® to treat cancer in Colombia, South America. Phase ll clinical trial results for late-stage colorectal cancer patients demonstrate that when DAVANAT® is co-administered with the chemotherapy drug 5-FU, survival increased by 46% over the best standard of care and reduced serious adverse events associated with chemotherapy.
CyDex Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to the company entitled "Sulfoalkyl Ether Cyclodextrin Compositions and Methods of Preparation Thereof." This patent, along with other previously issued technology patents, will provide broader protection for CyDex's Captisol® technology until 2028.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Melissa Rendeiro Gregorio, CNM 136 Sherman Ave, New Haven, CT 06511-5238 Ph: () - | Melissa Rendeiro Gregorio, CNM 136 Sherman Ave, New Haven, CT 06511-5238 Ph: (203) 562-5181 |
News Archive
BioParadox, Inc., a regenerative medicine company pioneering point-of-care biologic treatments for cardiovascular disease, today announced data supporting the use of VitaKine- Platelet Cell Therapy as a promising treatment for heart attack patients.
Researchers demonstrated that Lactobacillus rhamnosus can dose-dependently reestablish a balanced intestinal microbiome and counter the liver-damaging effects of alcohol consumption in mice to reverse the results of chronic alcohol-induced liver injury.
For the first time, MIT neuroscientists have shown they can control muscle movement by applying optogenetics - a technique that allows scientists to control neurons' electrical impulses with light - to the spinal cords of animals that are awake and alert.
Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that it has granted PROCAPS S.A. exclusive rights to market and sell DAVANAT® to treat cancer in Colombia, South America. Phase ll clinical trial results for late-stage colorectal cancer patients demonstrate that when DAVANAT® is co-administered with the chemotherapy drug 5-FU, survival increased by 46% over the best standard of care and reduced serious adverse events associated with chemotherapy.
CyDex Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to the company entitled "Sulfoalkyl Ether Cyclodextrin Compositions and Methods of Preparation Thereof." This patent, along with other previously issued technology patents, will provide broader protection for CyDex's Captisol® technology until 2028.
› Verified 5 days ago
Kristin Nowak, Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 46 Prince St, #207, New Haven, CT 06519 Phone: 203-787-2264 Fax: 203-497-9354 | |
Ms. Susan Debarge, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 2 Church St S, #209, New Haven, CT 06519 Phone: 203-787-2264 Fax: 203-497-9354 | |
Allison Mae Ipsen, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 374 Grand Ave # 3733, New Haven, CT 06513 Phone: 203-777-7411 | |
Ellen J Wormser, CNM LNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 374 Grand Avenue, Fair Haven Community Health Ctr, New Haven, CT 06513 Phone: 203-777-7411 Fax: 203-777-8506 | |
Deborah Lynn Meredith, LNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 55 Lock Street, New Haven, CT 06511 Phone: 203-432-0222 Fax: 203-432-7289 | |
Joan M Messner, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 46 Prince St, #207, New Haven, CT 06519 Phone: 203-787-2264 Fax: 203-787-5667 | |
Melissa Ann Lonergan, APRN CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 374 Grand Ave, Fair Haven Community Health Center, New Haven, CT 06513 Phone: 203-777-7411 |